biostudies-literatureNewman JDNCATS NIH HHSNHLBI NIH HHS1380-1395https://www.ebi.ac.uk/biostudies/studies/S-EPMC8545918biostudies-literatureUnknown144(17)<h4>Background</h4>Among patients with diabetes and chronic coronary disease, it is unclear if invasive management improves outcomes when added to medical therapy.<h4>Methods</h4>The ISCHEMIA (International Study of Comparative Health Effectiveness with Medical and Invasive Approaches) trials (ie, ISCHEMIA and ISCHEMIA-Chronic Kidney Disease) randomized chronic coronary disease patients to an invasive (medical therapy + angiography and revascularization if feasible) or a conservative approach (medical therapy alone with revascularization if medical therapy failed). Cohorts were combined after no trial-specific effects were observed. Diabetes was defined by history, hemoglobin A1c ≥6.5%, or use of glucose-lowering medication. The primary outcome was all-cause death or myocardial infarction CirculationOutcomes of Participants With Diabetes in the ISCHEMIA Trials.PMC8545918UL1 TR002243U01 HL105462U01 HL105907U01 HL105561UL1 TR001445U01 HL105565K23 HL125991Mazurek TGuzman LASenior RMahajan SBerger JSGajos GStone GWBangalore SEscobedo JDoerr RBhargava BBriguori CCheng HMancini GBJHochman JSFleg JLMaron DJPeteiro JBoden WEGarg PChaitman BRMaggioni APAnthopolos RVertes ARosenberg YDGonzalez-Juanatey JKunichoff DFKeltai MNewman JDReynolds HRfalseOutcomes of Participants With Diabetes in the ISCHEMIA Trials.<h4>Background</h4>Among patients with diabetes and chronic coronary disease, it is unclear if invasive management improves outcomes when added to medical therapy.<h4>Methods</h4>The ISCHEMIA (International Study of Comparative Health Effectiveness with Medical and Invasive Approaches) trials (ie, ISCHEMIA and ISCHEMIA-Chronic Kidney Disease) randomized chronic coronary disease patients to an invasive (medical therapy + angiography and revascularization if feasible) or a conservative approach (medical therapy alone with revascularization if medical therapy failed). Cohorts were combined after no trial-specific effects were observed. Diabetes was defined by history, hemoglobin A1c ≥6.5%, or use of glucose-lowering medication. The primary outcome was all-cause death or myocardial infarction 2021-01-01T00:00:00Z2021 Oct2026-05-08T02:01:12.549Z2024-11-05T16:21:36.537ZS-EPMC85459183452121710.1161/CIRCULATIONAHA.121.05443910.1161/circulationaha.121.054439